NCT05684380View on ClinicalTrials.gov

Efficacy and Safety of MAZ-101 in the Treatment of Persistent Allergic Rhinitis (PER)

PHASE3Not yet recruitingINTERVENTIONAL
Enrollment

514

Participants

Timeline

Start Date

September 30, 2024

Primary Completion Date

November 30, 2024

Study Completion Date

May 31, 2025

Conditions
Allergic Rhinitis
Interventions
DRUG

MAZ-101association

Experimental drug

DRUG

DYMISTA®

Active comparator

Sponsors

Lead Sponsor

EMS
All Listed Sponsors
lead

EMS

INDUSTRY

NCT05684380 - Efficacy and Safety of MAZ-101 in the Treatment of Persistent Allergic Rhinitis (PER) | Biotech Hunter | Biotech Hunter